DV
Dividend Vision

ONCO — Onconetix Inc

Onconetix Inc (ONCO)

Total return is -100.0% over the past 4.5 years, 190.0 points behind SPY at 90.0%. Its deepest 1-year drawdown was 99.6%.

Onconetix is a biotechnology company developing diagnostic tests for men's health and oncology, including Proclarix, a blood-based test for prostate cancer detection, and the PancreaSure test for pancreatic cancer screening through licensing agreements with LabCorp and Immunovia AB. The company does not currently distribute dividends. Onconetix appeals to investors seeking exposure to early-stage biotech innovation rather than current income.

ONCO key facts

Asset type
Stock
Asset class
Equity
Inception date
02/18/2022
Last close
$0.81
Market cap
$3,617,662
Average volume
233900.0
Beta
2.684
Payout ratio
0.0
P/E ratio
0.0007
Forward P/E
0.0
EPS
$1,377.40